

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

Claims 1-147 (Canceled).

Claim 148. (Previously Presented) A process comprising
treating cells in vitro with an effective dose of a substance that impairs cellular
peptide processing for MHC presentation,
wherein the substance is characterized in that tumor cells treated with the substance
are subject to specific lysis by CTL elicited by endogenous MHC class I dependent antigens
of the TAP-deficient variant of said tumor cell which has been transfected with the
stimulatory molecule B7-1; and
isolating cells which activate CD8+ T lymphocytes that selectively recognize cells
showing endogenous epitopes associated with impaired cellular peptide processing for MHC
presentation.

Claim 149. (Previously Presented) A process according to claim 148, wherein the
substance inhibits the function and/or expression of TAP.

Claim 150. (Currently Amended) A process according to claim 149, wherein the
substance is selected from the group consisting of ICP47 of HSV type 1, IE 12 of HSV type
2, a nucleotide sequence encoding a TAP inhibitor, a nucleotide sequence encoding a
polynucleotide that is complementary at least in part to the mRNA or DNA sequences
encoding TAP, antisense oligonucleotides, and RNA-destroying ribozyme.

Claim 151. (Previously Presented) A process according to claim 148, wherein the
substance inhibits the function and/or expression of the proteasome.

Claim 152. (Previously Presented) A process according to claim 151, wherein the substance is selected from the group consisting of a peptide aldehyde Z-Leu-Leu-H, Lactacystin, a nucleotide sequence encoding a proteasome inhibitor, a nucleotide sequence that is complementary to an mRNA or DNA sequence encoding proteasome, antisense oligonucleotides and RNA-destroying ribozyme.

Claim 153. (Previously Presented) A process according to claim 148, wherein the cells are autologous and/or hematopoietic cells.

Claim 154. (Previously Presented) A process according to claim 153, wherein the autologous and/or hematopoietic cells are dendritic cells or cells from cancer tissues.

Claim 155. (Previously Presented) A process comprising

- a) stimulating isolated immunological effector cells in vitro with cells isolated according to the method of claim 148; and
- b) isolating immunological effector cells that selectively recognize cells showing impaired cellular peptide processing for MHC presentation.

Claim 156. (Previously Presented) The process of claim 155, wherein the immunological effector cells are CD8+ T lymphocytes.

Claim 157. (Previously Presented) A composition comprising cells isolated according to the method of claim 148.

Claim 158. (Currently Amended) A process comprising administering to a mammal immunological effector cells T-cells that selectively recognize cells showing impaired cellular peptide processing for MHC presentation.

Claim 159. (Canceled).

Claim 160. (Previously Presented) A composition comprising

cells isolated according to the method of claim 148, or antigens or epitopes expressed by such cells; and
a pharmaceutically acceptable additive.

Claim 161. (Previously Presented) A composition comprising immunological effector cells isolated according to the method of claim 155.

Claim 162. (Canceled)

Claim 163. (Previously Presented) The method according to claim 148, further comprising

stimulating isolated immunological effector cells in vitro with said isolated cells which activate CD8+ T lymphocytes that selectively recognize cells showing endogenous epitopes associated with impaired cellular peptide processing for MHC presentation; and

isolating immunological effector cells that selectively recognize cells showing impaired cellular peptide processing for MHC presentation.

Claims 164 (Previously Presented) A composition comprising isolated immunological effector cells that selectively recognizes cells showing impaired cellular peptide processing for MHC presentation isolated according to the method of claim 163.